Company / Operating Cash Flow
4D Molecular Therapeutics, Inc. Operating Cash Flow History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$134.6M
FY2025
5-year range
-$134.6M / -$50.9M
FY2021-FY2025
Trend
-77.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$87M to -$135M over the past 2 years.
Based on SEC 10-K filings.
-$135M in FY2025.
Declined from -$87M to -$135M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow decreased 77.6% year-over-year.
- Peak operating cash flow was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.26 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$134.6M | -77.6% |
| FY2024 | -$75.8M | +12.6% |
| FY2023 | -$86.7M | -25.4% |
| FY2022 | -$69.1M | -35.8% |
| FY2021 | -$50.9M | -38.7% |
| FY2020 | -$36.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026